Andrew Guggenhime sold $692k of PCVX
PRESIDENT AND CFO at Vaxcyte, Inc.. 8,000 shares at an average of $86.51, traded Jan 21, 2025, filed Jan 22, 2025.
Score components
- +22RoleCFO
- +21Trade size$692k at market
- 0Share of holdings soldSold 6.8% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001649094-25-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 21, 2025 | MOption exercise Common Stock10b5-1 | +8,000 | $5.35 | $43k | 117,491 | Jan 22, 2025 |
| Jan 21, 2025 | SOpen-market sale Common Stock10b5-1 | -5,318 | $86.08 | $458k | 112,173 | Jan 22, 2025 |
| Jan 21, 2025 | SOpen-market sale Common Stock10b5-1 | -1,999 | $87.25 | $174k | 110,174 | Jan 22, 2025 |
| Jan 21, 2025 | SOpen-market sale Common Stock10b5-1 | -683 | $87.70 | $60k | 109,491 | Jan 22, 2025 |
| Jan 21, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -8,000 | $0.00 | $0 | 254,827 | Jan 22, 2025 |
Related signals
Other insiders at Vaxcyte, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Vaxcyte, Inc. | Elvia Cowan SVP, Finance & CAO | $1.6M 19,000 shares | -41% | |
| 23Weak | Vaxcyte, Inc. | Jim Wassil EVP, Chief Scientific Ofc, COO | $1.6M 18,000 shares | -11% | |
| 4Weak | Vaxcyte, Inc. | Jim Wassil EVP, Chief Scientific Ofc, COO | $128k 2,250 shares | -2% | |
| 11Weak | Vaxcyte, Inc. | Jim Wassil EVP, Chief Scientific Ofc, COO | $164k 2,715 shares | -2% | |
| 0Weak | Vaxcyte, Inc. | Jim Wassil CHIEF OPERATING OFFICER | $212k 3,477 shares | -2% | |
| 44Moderate | PCVXsell Vaxcyte, Inc. | Elvia Cowan SVP, FINANCE | $557k 11,623 shares | -44% | |
| 0Weak | Vaxcyte, Inc. | Mikhail Eydelman SVP, GEN COUNSEL & CORP SEC | $354k 5,000 shares | -11% | |
| 15Weak | Vaxcyte, Inc. | Andrew Guggenhime PRESIDENT AND CFO | $671k 8,000 shares | -7% | |
| 10Weak | Vaxcyte, Inc. | Mikhail Eydelman SVP, GEN COUNSEL & CORP SEC | $450k 5,000 shares | -15% | |
| 2Weak | Vaxcyte, Inc. | Mikhail Eydelman SVP, GEN COUNSEL & CORP SEC | $428k 5,000 shares | -15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.